

calcium receptor agonists, cobalamin, pertussis toxin, boron, dehydroepiandrosterone, activin and bone morphogenic protein.

b3
wrel. 19. The method of claim 1 wherein the Vitamin D analog is administered in combination with a cytotoxic agent comprising at least one of estramustine phosphate, prednimustine, cisplatin, 5-fluoro-uracil, melphalan, hydroxyurea, mitomycin, idarubicin, methotrexate, adriamycin, daunomycin, cyclophosphamide, doxorubicin, vincristine and prednisone.

b4 24. The method of claim 23 wherein the pharmaceutically acceptable organic carrier substance and the pharmaceutically acceptable inorganic carrier substance include at least one of water, salt and buffer solutions, alcohols, gum arabic, mineral and vegetable oils, benzyl alcohols, polyethylene glycols, gelatine, carbohydrates such as lactose, amylose or starch, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, and polyvinyl pyrrolidone.

REMARKS

Claims 1-12 and 18-25 are now pending in the application. Claims 1-12 and 18-25 stand rejected. Claims 13-17 have been cancelled.

Submitted herewith are marked up Specification and Claims in accordance with 37 C.F.R. 1.121(c)(1)(ii).

In accordance with 37 C.F.R. 1.136(a), a one month extension of time is timely submitted herewith to extend the due date of the response to the Office Action dated March 4, 2002 for the above-identified patent application from June 4, 2002, to and including July 4, 2002. In accordance with 37 C.F.R. 1.17(a), authorization to charge deposit account 01-2384 in the amount of \$110 to cover this extension of time request also is submitted herewith.

The objection to Claims 2, 4, 5, 18, 19 and 24 due to informalities is respectfully traversed. The Office Action indicated that the employment of parenthetical expressions "(analog V)", "(EB 1089)", "(DHEA)", "(hydroxydaunorubicin)", "(oncovin)" and "(buffer)" were considered to be informal. Correction was requested. Claims 2, 4, 5, 18, 19 and 24 have been amended to correct the indicated informalities. No new matter is presented by this amendment.